Secondary analyses from the CANTOS trial [104, 105] at least suggest that the IL-1β antibody canakinumab, which was effective to prevent cardiovascular events in patients with established coronary artery disease, was neutral with regard to arterial hypertension [106], although this trial also revealed that hsCRP level increases with increasing tertiles of blood pressure values at baseline. The gene discussed is IL1B; the disease is coronary artery disorder.